TRENDING TOPICS AND NEWS IN HCT AND CELLULAR THERAPY

Scientists report promising early results from a novel approach for preventing graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HCT).

Single-cell RNA sequencing of 40 idecabtagene vicleucel (ide-cel) products sheds light on the role that NF-κB signaling plays in the durability of response to chimeric antigen receptor (CAR)...

Chimeric antigen receptor (CAR) T-cell therapy has limited efficacy against T-cell acute lymphoblastic leukemia (T-ALL), but researchers have identified a target antigen and approach that they...

A real-world analysis of patients with relapsed/refractory multiple myeloma illustrates how infections contribute to inferior outcomes after treatment with idecabtagene vicleucel (ide-cel), a type...

Efmarodocokin alfa, an interleukin-22 agonist, demonstrates potential as prophylaxis against acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplantation...

A retrospective study underscores the value of contemporary grading systems for interpreting post–chimeric antigen receptor (CAR) T-cell therapy outcomes.